What I took from the screen shot was that it had
Post# of 72447
(Total Views: 340)
Posted On: 03/22/2020 4:53:32 PM
What I took from the screen shot was that it had Brilacidin listed below Biologics. I sure hope they weren't trying to say B was a biologic but that is what is inferred IMO.
Also, the ex-head of CDC appears to not be clued in on the Brilacidin head-to-head trial against Daptomycin a while back. If CDC not aware that B is a, or more likely THE, next generation of antibiotic compared to dapto... then the medical community, including the CDC, is sadly behind the times. They would still have no clue of this new arm of medicine, defensin mimetics, and how they have shown they can overcome many, if not all, of the superbugs beyond the scope of dapto... being able to handle and also work as both an anti-inflammatory and an anti-viral.
Brilacidin is a whole new ballgame to most of the researchers and, just like so many of us were skeptical as to it having so many advantages and next to no disadvantages as a drug, I believe the researchers will be in the same boat. That should change rapidly and Brilacidin will rise to the forefront as an investigational powerhouse.
Next 2-4 weeks should be exciting, but whether we get PRs as Brilacidin spreads thru various trials nobody has a clue IMO. Thus, silence may be the word during this time. But when we do hear about B in relation to C19 treatments, I expect it to be among the major contributors to handling of this calamity.
Also, the ex-head of CDC appears to not be clued in on the Brilacidin head-to-head trial against Daptomycin a while back. If CDC not aware that B is a, or more likely THE, next generation of antibiotic compared to dapto... then the medical community, including the CDC, is sadly behind the times. They would still have no clue of this new arm of medicine, defensin mimetics, and how they have shown they can overcome many, if not all, of the superbugs beyond the scope of dapto... being able to handle and also work as both an anti-inflammatory and an anti-viral.
Brilacidin is a whole new ballgame to most of the researchers and, just like so many of us were skeptical as to it having so many advantages and next to no disadvantages as a drug, I believe the researchers will be in the same boat. That should change rapidly and Brilacidin will rise to the forefront as an investigational powerhouse.
Next 2-4 weeks should be exciting, but whether we get PRs as Brilacidin spreads thru various trials nobody has a clue IMO. Thus, silence may be the word during this time. But when we do hear about B in relation to C19 treatments, I expect it to be among the major contributors to handling of this calamity.
(4)
(0)